Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Nisoldipine: Mechanism, Evidence, and Scope

    2026-10-18

    Scope and provenance. The available evidence for this overview is a commercial product description from APExBIO rather than an identity-matched primary research paper. Accordingly, the statements below distinguish documented product information from independently reported research findings. APExBIO lists Nisoldipine as SKU B1989 and describes it as a dihydropyridine calcium channel blocker intended for scientific research use. No primary citation, DOI, numerical efficacy dataset, or matched study report is available to support an independent literature assessment of this specific material.

    1. Documented identity and scientific context

    According to the APExBIO description, Nisoldipine has the molecular formula C20H24N2O6 and a molecular weight of 388.41. The supplier places it in the dihydropyridine class and associates it with L-type calcium-channel physiology, electrophysiology patch-clamp assays, cardiac myocytes, and animal models of coronary ischemia–reperfusion. These details establish the product’s documented chemical and research context, but they are not a substitute for independent identity confirmation or a primary study linking this particular catalog material to a reported outcome.

    The described context is consistent with a calcium channel blocker for cardiac research: the central scientific question is how modulation of voltage-gated calcium entry changes an electrical or tissue-level readout. That framing should not be expanded into a claim of clinical benefit, validated therapeutic performance, or general applicability across biological systems.

    2. Documented mechanism and measurement principle

    L-type Cav1.2 inhibition

    APExBIO reports that Nisoldipine selectively inhibits L-type Cav1.2 calcium channels with an IC50 of 10 nM. An IC50 is an assay-dependent concentration associated with half-maximal inhibition under a particular experimental definition; it is not, by itself, a universal binding constant, a measure of tissue exposure, or proof of efficacy in an organism.

    In an electrophysiology patch-clamp assay, a reduction in a channel-associated inward current is a relatively proximal readout of altered membrane conductance. That observation connects the pharmacological intervention to an electrical consequence, whereas changes in calcium-dependent signaling, contractility, cell survival, or infarct size are downstream observations. The distinction matters because a current-inhibition measurement can support channel modulation without demonstrating that a particular downstream phenotype was caused by Cav1.2 inhibition alone.

    Reported activity at delayed-rectifier potassium currents

    The same product description reports IC50 values of 23 μM for rapidly activating delayed-rectifier potassium current, IKr, and 40 μM for slowly activating delayed-rectifier potassium current, IKs. It also states approximately 30-fold selectivity for L-type calcium channels over these potassium currents. Those statements are not internally straightforward: if the listed values were directly comparable within the same assay framework, 23 μM versus 0.01 μM would correspond to roughly 2,300-fold, while 40 μM versus 0.01 μM would correspond to roughly 4,000-fold differences in nominal potency. Because the product description does not define the assays, normalization, channel constructs, or meaning of the 30-fold figure, these numbers cannot be converted into a reliable independent selectivity estimate.

    This unresolved point is scientifically important. A claim of selectivity depends not only on the numerical IC50 values but also on whether the currents were measured under comparable conditions and whether the concentrations reflect free compound, total compound, or another assay-specific quantity. The appropriate conclusion is therefore limited to the supplier’s reported activity profile, not a definitive ranking of Cav1.2 selectivity against IKr or IKs.

    3. Interpretation of the supplied properties and scope

    APExBIO characterizes Nisoldipine as insoluble in water and soluble in organic solvents including ethanol and DMSO. These are formulation and handling properties, not evidence of channel selectivity, cellular potency, or biological efficacy. They may affect how an assay result is interpreted because vehicle composition, effective free concentration, and compound availability can influence measured pharmacology, but the available description does not provide the controls or assay details needed to evaluate those factors.

    The named model systems also have different interpretive strengths. CHO cells expressing L-type calcium channels can provide a comparatively focused channel-current context, whereas cardiac myocytes provide more physiological cellular context but contain multiple conductances and regulatory pathways. A result in the former setting would primarily support channel-associated electrophysiological modulation; a result in the latter could reflect a combination of calcium-channel effects, other ionic currents, cellular state, and downstream signaling. The product description identifies these applications but supplies no dataset showing how Nisoldipine performed in either system.

    Documented claim What it can support What remains unestablished
    L-type Cav1.2 inhibition with a reported 10 nM IC50 A supplier-described pharmacological activity in an unspecified assay context Assay-independent potency, tissue exposure, or a particular downstream cardiac effect
    Reported activity against IKr and IKs at micromolar IC50 values The existence of a supplier-reported delayed-rectifier potassium-current profile A resolved, directly comparable selectivity ratio because assay definitions are unavailable
    Use in cardiac electrophysiology and calcium-channel physiology research A conceptual measurement role for current and calcium-signaling studies Performance in a named published experiment or superiority to another blocker
    Reduced infarct size in a dog coronary ischemia–reperfusion model, as stated by the product description An attributed animal-model cardioprotection claim Effect size, sample size, uncertainty, comparator, causal mechanism, and translational relevance

    4. Evidence availability and specific boundaries

    The product description states that animal studies reported cardioprotective effects, including reduced infarct size in a dog model of coronary ischemia–reperfusion. Infarct size is a consequential tissue-level endpoint, but it is downstream of many processes. Without the underlying study, the available material does not show the magnitude or precision of the effect, the number of animals, the comparator, or the experimental context. It also does not establish whether the outcome was mediated specifically by Cav1.2 inhibition rather than by broader changes in cardiac workload, electrical activity, vascular tone, or other pharmacological effects. These are interpretive boundaries, not claims that the underlying paper lacked such information.

    No direct comparison with another calcium-channel blocker, a vehicle control, or an alternative cardioprotective intervention is documented in the available material. Consequently, the information cannot support a comparative efficacy conclusion. Likewise, an in vitro current measurement, a cardiac-cell observation, and a dog ischemia–reperfusion outcome should not be treated as interchangeable evidence: they address different biological levels and establish different claims.

    The main limitations are therefore provenance and granularity. The evidence is anchored to one supplier description; the selectivity values lack assay metadata; the animal claim lacks a primary citation and outcome statistics; and no human, diagnostic, or treatment evidence is provided. The product page supports a research-context overview of Nisoldipine, but not an independent judgment of product quality, clinical utility, or reproducible performance in a particular assay.

    5. Concise factual synthesis

    Nisoldipine is documented by APExBIO as a dihydropyridine calcium channel blocker associated with L-type Cav1.2 inhibition and with weaker reported effects on delayed-rectifier potassium currents. Its most defensible conceptual scope is as a pharmacological perturbation relevant to calcium-channel physiology and cardiac electrophysiology research. Patch-clamp current inhibition would be a proximal measurement of altered ion-channel function, whereas cardioprotection in ischemia is a downstream animal-level claim. Because no identity-matched paper or primary outcome report is available, the mechanism and product properties can be described, but the reported selectivity, infarct-size effect, and broader biological significance remain supplier-attributed rather than independently established.